Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Preclinical-to-Clinical Anti-Cancer Drug Response Prediction and Biomarker Identification Using TINDL
Hostallero, David Earl , Wei, Lixuan , Wang, Liewei , Cairns, Junmei , Emad, Amin

Mayo Clinic

Genomics, Proteomics & Bioinformatics | February 11, 2023 | Volume: 21 | Issue: 3 | Pages: 535-550

10.1016/j.gpb.2023.01.006 | PMID 36775056 Get It

Abstract Prediction of the response of cancer patients to different treatments and identification of biomarkers of drug response are two major goals of individualized medicine. Here, we developed a deep learning framework called TINDL, completely trained on preclinical cancer cell lines (CCLs), to predict the response of cancer patients to different treatments. TINDL utilizes a tissue-informed normalization to account for the tissue type and cancer type of the tumors and to reduce the statistical discrepancies between CCLs and patient tumors. Moreover, by making the deep learning black box interpretable, this model identifies a small set of genes whose expression levels are predictive of drug response in the trained model, enabling identification of biomarkers of drug response. Using data from two large databases of CCLs and cancer tumors, we showed that this model can distinguish between sensitive and resistant tumors for 10 (out of 14) drugs, outperforming various other machine learning models. In addition, our small interfering RNA (siRNA) knockdown experiments on 10 genes identified by this model for one of the drugs (tamoxifen) confirmed that tamoxifen sensitivity is substantially influenced by all of these genes in MCF7 cells, and seven of these genes in T47D cells. Furthermore, genes implicated for multiple drugs pointed to shared mechanism of action among drugs and suggested several important signaling pathways. In summary, this study provides a powerful deep learning framework for prediction of drug response and identification of biomarkers of drug response in cancer. The code can be accessed at https://github.com/ddhostallero/tindl.
Current status of clinical outcome measures in inclusion body myositis: a systematised review
Goyal, Namita , Alfano, Lindsay N. , Garand, Kendrea L. , Mochel, David, Badrising, Umesh A. , Machado, Pedro , Pagkatipunan, Ruben, Funaro, Melissa , Schmidt, Jens , Kushlaf, Hani , Schiopu, Elena , Goyal, Neelam , d’Alessandro, Miriana , Conticini, Edoardo , Cruz-Coble, Betsaida, Machado, Pedro M , Roy, Bhaskar , Lucchini, Matteo , Lilleker, James B , Naddaf, Elie , Adler, Brittany L. , Malandraki, Georgia A. , Wang, Leo L. , Stipancic, Kaila L. , Goyal, Neelam, Lloyd, Thomas E

Mayo Clinic

Clinical and Experimental Rheumatology | February 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/ifacv3 | PMID 36762744 Get It

The value of embedded palliative care in the emergency department
Neugarten, Carter , Baldeo, Ryan , Tian, Katherine, Piscitello, Gina M. , O’Mahony, Sean , Kaginele, Pranita , Wang, David H., Tian, Katherine

Mayo Clinic

Academic Emergency Medicine | February 9, 2023 | Volume: 30 | Issue: 8 | Pages: 870-873

10.1111/acem.14684 | PMID 36757676 Get It

A Delphi Method for Development of a Barrett’s Esophagus Question Prompt List as a Communication Tool for Optimal Patient-physician Communication
Kamal, A. N. , Wang, Chih-Hung Jason, Diehl, David L. , DuCoin, Christopher , Dunst, Christy M. , Iyer, Prasad G. , Katzka, David A. , Konda, Vani J. , Muthusamy, Raman, Otaki, Fouad , Rubenstein, Joel H. , Shaheen, Nicholas J. , Smith, Michael S. , Sujka, Joseph , Tatum, Roger P. , Ujiki, Michael , Wani, Sachin , Clarke, John O. , Clarke, J , Otaki, Fouad , Kamal, Afrin N., Triadafilopoulos, George , Falk, Gary W. , Muthusamy, Raman, Pleskow, Douglas K. , Sharma, Prateek , Swanström, Lee L. , Trindade, Arvind J.

Mayo Clinic

Journal of Clinical Gastroenterology | February 8, 2023 | Volume: 58 | Issue: 2 | Pages: 131-135

10.1097/mcg.0000000000001832 | PMID 36753462 Get It

Background Methods: The question prompt list content was derived through a modified Delphi process consisting of 3 rounds. In round 1, experts provided 5 answers to the prompts “What general questions should patients ask when given a new diagnosis of Barrett’s esophagus” and “What questions do I not hear patients asking, but given my expertise, I believe they should be asking?” Questions were reviewed and categorized into themes. In round 2, experts rated questions on a 5-point Likert scale. In round 3, experts rerated questions modified or reduced after the previous rounds. Only questions rated as “essential” or “important” were included in Barrett’s esophagus question prompt list (BE-QPL). To improve usability, questions were reduced to minimize redundancy and simplified to use language at an eighth-grade level (Fig. 1). Results: Twenty-one esophageal medical and surgical experts participated in both rounds (91% males; median age 52 years). The expert panel comprised of 33% esophagologists, 24% foregut surgeons, and 24% advanced endoscopists, with a median of 15 years in clinical practice. Most (81%), worked in an academic tertiary referral hospital. In this 3-round Delphi technique, 220 questions were proposed in round 1, 122 (55.5%) were accepted into the BE-QPL and reduced down to 76 questions (round 2), and 67 questions (round 3). These 67 questions reached a Flesch Reading Ease of 68.8, interpreted as easily understood by 13 to 15 years olds. Conclusions: With multidisciplinary input, we have developed a physician-derived BE-QPL to optimize patient-physician communication. Future directions will seek patient feedback to distill the questions further to a smaller number and then assess their usability.
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Wang, Yucai , Jain, Preetesh , Locke, Frederick L. , Maurer, Matthew J. , Frank, Matthew J. , Muñoz, Javier , Dahiya, Saurabh , Beitinjaneh, Amer , Jacobs, Miriam T. , McGuirk, Joseph P. , Hill, Brian T. , Dorritie, Kathleen , Oluwole, Olalekan O. , Deol, Abhinav , Wang, Trent , Banerjee, Rahul , Miklos, David B. , Rapoport, Aaron P. , Lekakis, Lazaros J. , Neelapu, Sattva S. , Wang, Michael , Munoz, Javier L , Vose, Julie , Goy, Andre Henri , Oluwole, Olalekan O , Deol, Abhinav , Paludo, Jonas , Wang, Trent , Banerjee, Rahul , Miklos, David B , Rapoport, Aaron P , Neelapu, Sattva S , Lin, Yi , Wang, Michael L , Jain, Michael D , Maurer, Matthew , McGuirk, Joseph , Wang, Yucai , Dahiya, Saurabh , Jacobs, Miriam T , Locke, Frederick L , Jain, Preetesh , Vose, Julie M. , Andreadis, Charalambos Babis , Paludo, Jonas , Shah, Bijal , Ghobadi, Armin , Lin, Yi , Jain, Michael D.

Mayo Clinic

Journal of Clinical Oncology | February 8, 2023 | Volume: 41 | Issue: 14 | Pages: 2594-2606

10.1200/jco.22.01797 | PMID 36753699 Get It

PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II ZUMA-2 trial, which showed best overall and complete response rates of 91% and 68%, respectively. We report clinical outcomes with brexu-cel in the standard-of-care setting for the approved indication. PATIENTS AND METHODS Patients who underwent leukapheresis between August 1, 2020 and December 31, 2021, at 16 US institutions, with an intent to manufacture commercial brexu-cel for relapsed/refractory MCL, were included. Patient data were collected for analyses of responses, outcomes, and toxicities as per standard guidelines. RESULTS Of 189 patients who underwent leukapheresis, 168 (89%) received brexu-cel infusion. Of leukapheresed patients, 79% would not have met ZUMA-2 eligibility criteria. Best overall and complete response rates were 90% and 82%, respectively. At a median follow-up of 14.3 months after infusion, the estimates for 6- and 12-month progression-free survival (PFS) were 69% (95% CI, 61 to 75) and 59% (95% CI, 51 to 66), respectively. The nonrelapse mortality was 9.1% at 1 year, primarily because of infections. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 8% and 32%, respectively. In univariable analysis, high-risk simplified MCL international prognostic index, high Ki-67, TP53 aberration, complex karyotype, and blastoid/pleomorphic variant were associated with shorter PFS after brexu-cel infusion. Patients with recent bendamustine exposure (within 24 months before leukapheresis) had shorter PFS and overall survival after leukapheresis in intention-to-treat univariable analysis. CONCLUSION In the standard-of-care setting, the efficacy and toxicity of brexu-cel were consistent with those reported in the ZUMA-2 trial. Tumor-intrinsic features of MCL, and possibly recent bendamustine exposure, may be associated with inferior efficacy outcomes.
Human Airway Basal Cells Undergo Reversible Squamous Differentiation and Reshape Innate Immunity
Black, Katharine E., Phung, Thien‐Khoi N. , Thundivalappil, Sujatha, Xu, Jie , Lapey, Allen , Lerou, Paul H. , Que, Jianwen, Park, Jin‐Ah , Hurley, Bryan P. , Mou, Hongmei , Que, Jianwen , Mou, Hongmei , Park, Jin-Ah , Que, Jianwen , Zhang, Yihan , Lin, Tian , Wang, Wei , Zhang, Cheng , Hariri, Lida P. , Li, Hu , Ai, Xingbin

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | February 8, 2023 | Volume: 68 | Issue: 6 | Pages: 664-678

10.1165/rcmb.2022-0299oc | PMID 36753317 Get It

Abstract Histological and lineage immunofluorescence examination revealed that healthy conducting airways of humans and animals harbor sporadic poorly differentiated epithelial patches mostly in the dorsal noncartilage regions that remarkably manifest squamous differentiation. In vitro analysis demonstrated that this squamous phenotype is not due to intrinsic functional change in underlying airway basal cells. Rather, it is a reversible physiological response to persistent Wnt signaling stimulation during de novo differentiation. Squamous epithelial cells have elevated gene signatures of glucose uptake and cellular glycolysis. Inhibition of glycolysis or a decrease in glucose availability suppresses Wnt-induced squamous epithelial differentiation. Compared with pseudostratified airway epithelial cells, a cascade of mucosal protective functions is impaired in squamous epithelial cells, featuring increased epithelial permeability, spontaneous epithelial unjamming, and enhanced inflammatory responses. Our study raises the possibility that the squamous differentiation naturally occurring in healthy airways identified herein may represent “vulnerable spots” within the airway mucosa that are sensitive to damage and inflammation when confronted by infection or injury. Squamous metaplasia and hyperplasia are hallmarks of many airway diseases, thereby expanding these areas of vulnerability with potential pathological consequences. Thus, investigation of physiological and reversible squamous differentiation from healthy airway basal cells may provide critical knowledge to understand pathogenic squamous remodeling, which is often nonreversible, progressive, and hyperinflammatory.
Griseofulvin Radiosensitizes Non–Small Cell Lung Cancer Cells and Activates cGAS
Wang, Xing , Raman, Natasha , Lemtiri-Chlieh, Ghali , Chang, Jinhee , Jagtap, Shreya , Chowdhury, Dipanwita D. , Ballew, Matthew , Carrieri, Francesca A. , Nguyen, Triet , Nugent, Katriana , Peck, Travis , Levine, Michelle S. , Chan, Aaron , Lam, Christine , Malek, Reem , Hoang, Tung , Phillips, Ryan , Cheng, Zhuoan , Taparra, Kekoa , Connis, Nick , Hann, Christine L. , Holland, Andrew J. , Lafargue, Audrey , Chowdhury, Dipanwita Dutta , Carrieri, Francesca Anna , Holland, Andrew , Tran, Phuoc T , Lafargue, Audrey , Wang, Hailun , Peck, Travis

Mayo Clinic

Molecular Cancer Therapeutics | February 8, 2023 | Volume: 22 | Issue: 4 | Pages: 519-528

10.1158/1535-7163.mct-22-0191 | PMID 36752776 Get It

Abstract Extra copies of centrosomes are frequently observed in cancer cells. To survive and proliferate, cancer cells have developed strategies to cluster extra-centrosomes to form bipolar mitotic spindles. The aim of this study was to investigate whether centrosome clustering (CC) inhibition (CCi) would preferentially radiosensitize non–small cell lung cancer (NSCLC). Griseofulvin (GF; FDA-approved treatment) inhibits CC, and combined with radiation treatment (RT), resulted in a significant increase in the number of NSCLC cells with multipolar spindles, and decreased cell viability and colony formation ability in vitro. In vivo, GF treatment was well tolerated by mice, and the combined therapy of GF and radiation treatment resulted in a significant tumor growth delay. Both GF and radiation treatment also induced the generation of micronuclei (MN) in vitro and in vivo and activated cyclic GMP-AMP synthase (cGAS) in NSCLC cells. A significant increase in downstream cGAS-STING pathway activation was seen after combination treatment in A549 radioresistant cells that was dependent on cGAS. In conclusion, GF increased radiation treatment efficacy in lung cancer preclinical models in vitro and in vivo. This effect may be associated with the generation of MN and the activation of cGAS. These data suggest that the combination therapy of CCi, radiation treatment, and immunotherapy could be a promising strategy to treat NSCLC.
Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
Powell, Marissa , Mara, Kristin C. , Bansal, Radhika , Hathcock, Matthew , Khurana, Arushi , Bennani, N. Nora , Wang, Yucai , Villasboas, José C. , Ansell, Stephen M. , Johnston, Patrick B. , Barreto, Jason N. , Powell, Marissa Z , Paludo, Jonas , Villasboas, Jose Caetano , Barreto, Jason N , Bennani, N Nora , Wang, Yucai , Mara, Kristin C , Paludo, Jonas , Lin, Yi

Mayo Clinic

Cancer Medicine | February 8, 2023 | Volume: 12 | Issue: 8 | Pages: 9228-9235

10.1002/cam4.5665 | PMID 36752185 Get It

AbstractBackgroundIt is unknown whether serum procalcitonin (PCT) concentration monitoring can differentiate between bacterial infection or cytokine release syndrome (CRS) when chimeric antigen receptor T‐cell (CAR‐T) recipients present with a constellation of signs and symptoms that may represent both complications.ObjectiveThe objective of the study was to assess the utility of serum PCT concentrations as a biomarker of bacterial infection in CAR‐T recipients.Study designThis single‐center, retrospective, medical record review evaluated patients prescribed CAR‐T therapy until death or 30 days after infusion. Logistic regression modeling determined the association between elevated serum PCT concentrations within 48 h of fever onset and microbiologically confirmed infection. Secondary outcomes included clinically suspected infection, CAR‐T toxicity rates, and broad‐spectrum antibiotic usage. Predictive performance of PCT was assessed by area under the receiver operating characteristic curve (AUC).ResultsThe 98 included patients were a median age of 63 (IQR: 55–69) years old, 47 (48%) were male, and 87 (89%) were Caucasian. Baseline demographics and clinical characteristics were similar between patients with and without a bacterial infection. Serum PCT >0.4 ng/mL within 48 h of fever was significantly associated with a microbiologically confirmed bacterial infection (OR: 2.75 [95% CI: 1.02–7.39], p = 0.045). Median PCT values in patients with and without confirmed infections were 0.40 ng/mL (IQR: 0.26, 0.74) and 0.26 ng/mL (IQR: 0.13, 0.47), respectively. The AUC for PCT to predict bacterial infection was 0.62 (95% CI 0.48–0.76). All patients experienced CRS of some grade, with no difference in CRS severity based on elevated PCT. Broad‐spectrum antibiotics were used for a median of 45% and 23% of days in those with and without confirmed infection, respectively (p = 0.075).ConclusionElevated serum PCT concentrations above 0.4 ng/mL at time of first fever after CAR‐T infusion was significantly associated with confirmed bacterial infection. Furthermore, rigorous, prospective studies should validate our findings and evaluate serial PCT measurements to optimize antimicrobial use after CAR‐T therapy.
Engagement of ICOS in tissues promotes establishment of CD8+ tissue-resident memory T cells
Huggins, Matthew A. , Lu, Hanbin, Wang, Haiguang , Mittelsteadt, Kristen , Campbell, Daniel , Peng, Changwei , Wanhainen, Kelsey M. , Georgiev, Hristo , Hogquist, Kristin Ann , Silva, Henrique Borges da , Jameson, Stephen C.

Mayo Clinic

The Journal of Immunology | February 7, 2023 | Volume: 206 | Issue: 1_Supplement | Pages: 24.06-24.06

10.4049/jimmunol.206.supp.24.06 Get It

Abstract Resident memory T cells (TRM) provide localized protective immunity in non-lymphoid tissues, but the signals and interactions within non-lymphoid tissues involved in generating TRM are incompletely defined. Inducible T-cell costimulator (ICOS) is a costimulatory molecule with well elaborated roles in regulating differentiation of CD4+ T cell populations, its function in CD8+ T cells is largely unexplored. With acute infection models, we found that ICOS-deficient CD8+ T cells showed minimal defects in the initial effector expansion and the generation of recirculating memory subsets. However, consistent with its high expression in TRM, ICOS deficiency significantly compromised the establishment of CD8+ TRM cells in diverse non-lymphoid tissues. We further confirmed that rather than pre-programming the TRM fate during initial T cell priming, the interaction between ICOS ligand (ICOSL) and ICOS in the non-lymphoid tissues during CD8+ T cell recruitment is critical for efficient tissue retention and acquisition of tissue residency signatures. ICOS signaling through PI3K pathway is key for TRM generation and ICOS stimulation promotes downregulation of KLF2, a transcription factor that regulates T cell trafficking, in CD8+ T cells after entering non-lymphoid tissues. Altogether, our data illustrate that engagement of ICOS is one of the critical local costimulatory cues that promote the establishment of tissue-resident populations, with potential implication for therapeutic manipulation.